Liver/Biliary Disorders News

BOSTON — Transarterial chemoembolization with vitamin K dosing improved anticancer outcomes of objective response and progression-free survival in patients with hepatocellular carcinoma, according to a researcher at The Liver Meeting.

BOSTON — Resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis was linked to long-term survival after bariatric surgery, similar to that of patients without baseline MASH, according to a presenter.

BOSTON — An educational program for transplant nurse coordinators did not improve advanced care planning among patients with decompensated cirrhosis, suggesting that provider training alone is “insufficient” to create significant change.

SAN DIEGO — Patients with rheumatoid arthritis who receive hydroxychloroquine demonstrate a lower risk for nonalcoholic fatty liver disease, according to data presented at ACR Convergence 2023.

BOSTON — Metabolic dysfunction-associated steatohepatitis is currently the most common indication for liver transplantation in patients with hepatocellular carcinoma, increasing from 10% in 2013 to 31% in 2022, according to a presenter.

BOSTON — Researchers reported similar patient and allograft survival 1 year after liver transplantation between COVID-19 positive and negative donors, showing potential for expanding organ access, according to data at The Liver Meeting.

BOSTON — Triple combination of vebicorvir, imdusiran and nucleos(t)ide reverse transcriptase inhibitor did not improve markers of active hepatitis B infection in virologically suppressed patients vs. treatment regimens without vebicorvir.

BOSTON — An intensive, advanced practice provider-guided weight loss program helped patients with metabolic dysfunction-associated steatotic liver disease achieve statistically significant weight loss vs. standard of care.

BOSTON — Researchers recommended the FibroScan-aspartate aminotransferase score as a noninvasive biomarker to stratify patients at risk for metabolic dysfunction-associated steatohepatitis, when used with different cutoff points for HbA1C.

BOSTON — A new model forecasted a “substantial clinical burden” of metabolic dysfunction-associated steatotic liver disease in the next 30 years, including twice as many cases of liver cancer and triple the need for liver transplantation.